Close Menu

NEW YORK (GenomeWeb News) – The Van Andel Institute plans to become a hub of epigenetics research by developing a consortium of four US academic institutions and one from abroad that will collaborate to develop new personalized epigenetic treatments.

The initiative will be led by Peter Jones, director of research and chief scientific officer at the Van Andel Research Institute, which is based at VAI's headquarters in Grand Rapids, Mich. He already is working with international research partners on epigenetic therapies to treat cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.

In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.